NVS250516C135000
- 0.00
- 0.000.00%
Novartis AG Newsroom
Key Deals This Week: Gold Fields, Palo Alto, Novartis, LendingClub and More
Novartis AG (NOVN) Receives a Hold From Berenberg Bank
Regulus CVR May Be Worth $3-$4 a Share in Novartis Deal - Analyst
Novartis AG (NOVN) Receives a Hold From Goldman Sachs
Sector Update: Health Care Stocks Rise Wednesday Afternoon
Top Midday Gainers
Sector Update: Health Care
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
Top Midday Stories: Nvidia, Oracle Rush Chip Shipments Ahead of Export Rule; Super Micro Cuts Fiscal Q3 EPS, Net Sales Guidance
Research Alert: CFRA Keeps Hold Opinion On Adss Of Novartis Ag
Novartis (NVS.US) plans to acquire Regulus Therapeutics (RGLS.US) for up to $1.7 billion.
Novartis AG (NVS.US) announced on Wednesday that it has reached an agreement to acquire the USA biotechnology company Regulus Therapeutics Inc. (RGLS.US), and this Trade could be worth up to 1.7 billion USD.
Deutsche Bank Sticks to Its Buy Rating for Novartis AG (NOVN)
Novartis: Transaction Is Expected to Close in Second Half of 2025
Novartis: Regulus Therapeutics Is U.S. Biotech Focused on MicroRNA Therapeutics
Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment
Novartis to Buy
Novartis To Buy Regulus Therapeutics For $7.00/Shr In Cash, With Potential To Receive Addl $7.00/Shr In Cash Through Contingent Value Right, For Total Equity Value Of Up To About $1.7B
Express News | Regulus Therapeutics Enters Into Agreement to Be Acquired by Novartis AG
Press Release: Regulus Therapeutics Enters Into Agreement to Be Acquired by Novartis AG
Novartis AG (NVS) Q1 2025 Earnings Call Transcript Summary